Table 2. Characteristics of NSCLC in patients from OCTOMUT study.
| N = 114 | |
|---|---|
| Median time (days) between first symptoms and diagnosis | 55.0 |
| Adenocarcinoma, n (%) | 109 (95.6) |
| Histological stage at diagnosis, n (%) | |
| I–II | 8 (7.0) |
| III | 15 (13.2) |
| IV | 91 (79.8) |
| Localization of metastases, n (%) | |
| Pleural cavity | 43/91 (47.3) |
| Lung | 29/91 (31.9) |
| Lymph nodes | 18/91 (19.8) |
| EGFR mutation, n (%) | |
| Exon 19 | 53 (46.5) |
| Exon 21 | 46 (40.4) |
| Exon 18 | 9 (7.9) |
| Exon 20 | 6 (5.2) |
| Number of lines of treatment before EGFR TKI, n (%) | |
| 0 | 94 (83.2) |
| 1 | 16 (14.2) |
| ≥2 | 3 (2.6) |
| MD | 1 |
| Type of EGFR TKI, n (%) | |
| Gefitinib | 62 (54.4) |
| Erlotinib | 45 (39.6) |
| Afatinib | 2 (1.8) |
| Undefined | 5 (4.2) |
MD, missing data.